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Abstract
FAM171B is a relatively uncharacterized protein that contains fourteen
consecutive glutamine residues within its primary amino acid sequence; thus it is a
polyglutamine (polyQ) protein. PolyQ proteins are interesting because mutations within
the polyQ tract have been linked to a number of severe neurodegenerative diseases
including Huntingtons Disease (HD). To date, there are minimal published data regarding
FAM171B and its molecular function, such that both expression levels and intracellular
localization have yet to be definitively determined. Using immunohistochemical and in
situ hybridization analyses, our lab has recently found that FAM171B is expressed
throughout the mouse brain. This current study attempts to build off this information to
identify the intracellular localization of FAM171B in several different nervous system
cell types including: a human glioblastoma cell line (U138), a human neuroblastoma cell
line (SH-SY5Y), and mouse brain primary neurons. Using immunofluorescence,
FAM171B-GFP fusion proteins, and live cell imaging (coupled with confocal
microscopy) our data indicate that FAM171B has a predominantly vesicular/punctate
staining within the cytoplasm of cells. Furthermore, colocalization studies using organelle
specific markers shows that FAM171B localizes to both endosomes and cellular regions
near the plasma membrane. Taken together, our data suggests that FAM171B may play a
vesicle trafficking role within cells of the nervous system.
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Chapter 1
Introduction

Homopeptide repeats are consecutive stretches of the same amino acid within a
protein’s primary sequence. They are a common protein motif, and it has been suggested
that at least certain homopeptide amino acid repeats may serve as protein-protein
interaction domains (1). Polyglutamine (polyQ) tracts, a specific type of homopeptide
repeat consisting of multiple consecutive glutamine (Q) amino acid residues are present
in more than 60 human proteins (2). Indeed, some lower organisms (such as the amoeba
Dictyostellium discoideum) possess several hundred (3). PolyQ tracts in proteins are often
polymorphic in repeat copy number. However the function of polyQ tracts within
proteins, and the putative consequence of this normal Q repeat copy number variation has
yet to be definitively determined (2,3).
Interestingly, expansion mutation of polyQ (CAG repeats) tracts well beyond
their normal polymorphic range in certain proteins leads to severe inherited
neurodegenerative diseases, known collectively as polyglutamine diseases. In 1991,
Fischbeck and coworkers first reported the disease associated expansion of CAG repeat
in exon 1 of the androgen receptor gene in patients of spinal and bulbar muscular atrophy
(SBMA) (4). Since then, similar genetic mutations of the CAG repeat expansion in the
coding regions of genes other than androgen receptor gene have been found in other
inherited neurodegenerative disorders. To date, a total of nine polyQ disorders have been
described: six spinocerebellar ataxias (SCA) types 1, 2, 3, 6, 7, 17; huntington’s disease
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(HD); dentatorubral pallidoluysian atrophy (DRPLA); and spinal and bulbar muscular
atrophy. In each disease, the specific translated polyQ protein leads to dysfunction and
degeneration of select neuronal subpopulations (Table1)
Table 1. Summary of the nine inherited Polyglutamine disorders

Disease
Huntington's
disease (HD)
Spinocerebellar
ataxia 1
(SCA1)
Spinocerebellar
ataxia 2
(SCA2)
Spinocerebellar
ataxia 3
(SCA3)
Dentatorubralpallidoluysian
atrophy
(DRPLA)
Spinocerebellar
ataxia 6
(SCA6)
Spinocerebellar
ataxia 7
(SCA7)

Disease
Protein

Normal
Subcellular
Localization

Huntingtin
(htt)

Cytoplasm

Ataxin-1

Nuclear and
cytoplasmic

Ataxin-2

Affected
Brain
Regions
Striatum and
cortex

CAG Repeat Length
Normal Pathological
6-35

36-121

Cerebellum

6-39

41-83

Cytoplasmic

Cerebellar
Purkinje cells

14-32

34-77

Ataxin-3

Nuclear and
cytoplasmic

Ventral pons
and substantia
nigra

12-40

62-86

Atrophin-1

Nuclear and
cytoplasmic

3-38

49-88

Ataxin-6

Membrane
associated

Cerebellar
Purkinje cells

4-18

21-30

Nuclear and
cytoplasmic

Cerebellar
Purkinje cells,
brain stem,
spinal cord

7-18

38-200

Nuclear and
cytoplasmic

Motor
neurons

6-36

38-62

Nuclear

Cerebellar
Purkinje cells

25-43

45-63

Ataxin-7

Spinal and
bulbar
Androgen
muscular
receptor (AR)
atrophy
(SBMA)
Spinocerebellar
ataxia 17
TBP
(SCA17)

Cerebral
cortex
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PolyQ diseases are relatively rare, averaging 1–10 cases per 100,000 people (5).
Of polyQ disorders, HD and SCA3 have the highest prevalence worldwide (6).
While the genes associated with the different polyQ diseases are structurally and
functionally distinct, there are commonalities across all of these diseases. With the
exception of SBMA, which is X-linked (and displays sex-limited inheritance), all other
polyQ diseases are inherited in autosomal dominant pattern (7). All are
neurodegenerative disorders, with disease onset typical in midlife and slowly progressive
phenotypes. Certain pathologic molecular processes have been implicated in almost all of
the polyQ diseases, including protein aggregation, proteolytic cleavage, transcription
dysregulation, autophagy impairment, and mitochondrial dysfunction (7).
Curiously, polyQ containing proteins are ubiquitously expressed throughout the
body, while the pathology is primarily restricted to neuronal tissue, displaying cell-type
specificity or selective vulnerability (8). The mechanisms that are responsible for this
specificity are largely unknown (7). However, the amino acid context of the polyQ
proteins and their interacting protein partners may help determine the selective neuronal
cell loss seen in distinct brain regions affected in polyQ diseases (9).
Importantly, the length of the polyQ repeat is critical to pathogenesis and for each
disease (Table 1). There seems to be a critical threshold of polyQ expansion that must be
exceeded in order to cause disease (10,11). For example, Huntington has a polyQ tract at
its amino-terminus with a normal repeat length ranging from 5-35 repeats. In contrast, the
polyQ tract in HD patients is abnormally expanded to greater than 40 consecutive
glutamine residues and residues longer than 60 elicit juvenile forms of HD (Table1)
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(11,12). Interestingly, the longer the polyQ repeat tract length- the more severe HD
manifests (13). Also, expanded polyQ regions are inherently unstable and tend to expand
further, resulting in an earlier age of onset and a more severe disease phenotype in
successive familial generations (13). Indeed, this “genetic anticipation” is a prominent
feature of all polyQ diseases (13).
The best studied pathology, HD, usually involves the loss of neurons in the
striatum and layers III and V of the cortex, which affects muscle coordination and leads
to cognitive impairment and psychiatric problems (5). The IT15 gene that encodes the
Huntingtin (Htt) protein is located on the short arm of chromosome four. Huntingtin is
widely expressed in neuronal and non‐neuronal tissues, but its level in the striatum is
higher than in other organs (14). The functions of normal htt are not yet completely
known, but it is suggested that non‐mutated htt is involved in cellular trafficking and may
function as a scaffold protein (15).
Spinocerebellar ataxia types 1–3, 6, and 7 are the most frequent among autosomal
dominantly inherited cerebellar ataxia (ADCA) syndromes and account for 50-60% of all
families affected by ADCA worldwide (16). Major symptoms of ataxia, such as
imbalance and incoordination, are indicative of impairment of cerebellar functions, which
results mainly from a massive loss of Purkinje cells. Ataxias are often accompanied by
dysarthria, rigidity, and dystonia, as well as by oculomotor disorders (17).
Dentatorubral-pallidoluysian atrophy (DPRLA) is caused by a mutation in the
atrophin‐1 gene that results in an abnormally expanded polyQ tract in this protein (Table
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1). DRPLA patients show a wide variety of progressive neurological deficits like ataxia,
myoclonus, epilepsy, and dementia (5).
Spinal and bulbar muscular atrophy (SBMA), or Kennedy's disease, is
characterized by slowly progressing muscle weakness and atrophy of the bulbar, facial,
and limb muscles (18). Pathologically, SBMA is associated with loss of motor neurons in
the spinal cord and brainstem. SBMA is caused by an abnormal expansion of CAG
repeats in exon 1 of the androgen receptor (AR) gene on chromosome Xq11-12 (19).
Determination of the structure of polyQ regions has been difficult, as they appear
to be unstable (1). However, abnormally expanded polyQ stretches likely undergo a
conformational transition to a ß-sheet rich structure, which causes these proteins to
assemble into amyloid fibril insoluble aggregates (12). Indeed, neuronal inclusion bodies
composed of aggregated expanded polyQ proteins have been linked to cell death and
neurodegeneration leading to behavioral and physical impairments (12). Several studies
have linked these polyQ aggregates to cellular toxicity. For example, overexpression of
chaperone proteins slow aggregation and decreased toxicity in both cellular and animal
models (20). Both loss-of-normal-function and toxic-gain of function mechanisms have
been posited to explain toxicity, but the case for latter is stronger (20). Unfortunately, to
date, there is neither a cure nor prevention for these devastating diseases (9,13)
Our lab is interested in characterizing FAM171B, a novel polyQ protein that has
yet to be linked to a neurodegenerative disease. Bioinformatic analysis suggests that,
similar to huntingtin, FAM171B has a stretch of consecutive glutamine amino acids near
its amino terminus (unpublished data). However, there is minimal information published
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regarding the molecular function of this novel protein. For example, it is unknown
whether the polyQ tract is polymorphic in humans. Similarly, FAM171B expression
levels and subcellular localization have yet to be definitively determined.
Recent studies in our lab using in situ hybridization and immunohistochemistry
strongly suggest that FAM171B is expressed throughout the brain- elevating its status as
a candidate gene for an as yet molecularly uncharacterized neurodegenerative disease
(unpublished data). Furthermore, examination of regions within the brain, indicate that
FAM171B is expressed more prominently in certain brain areas compared to others. For
example, the hippocampus shows very high FAM171B expression at both the mRNA and
protein level. The hippocampus is a complex brain structure embedded deep into
temporal lobe and it has a major role in learning and memory. The hippocampus is also
important in spatial navigation, emotional behavior and regulation of hypothalamic
functions (21). Many polyQ diseases such as HD, SBMA, DRPLA result in dementia and
impaired memory (22) which could be due to failure in hippocampal activity. High levels
of FAM171B are also found in the cerebellum. The cerebellum plays an important role in
the motor system coordination. Severe abnormalities of movement are produced by
pathologies of the cerebellum (23). Other non-motor functions of cerebellum includes
attention, executive control, language, working memory, learning, pain, emotion, and
addiction (24). In many polyQ diseases atrophic changes in the cerebellum is a prominent
feature (13).
Further bioinformatic analysis suggests that FAM171B has a number of other
interesting protein domains including an AT-Hook DNA binding domain, glycosylation
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sites, and transmembrane regions (unpublished data). However, whether any of these
putative domains actually function as predicted remains to be determined. Thus, these in
silico analyses provide hints into molecular structure and function that need to be
empirically verified via benchtop experiments.
An AT- hook is a small DNA binding motif and it was first described in high
mobility group non-histone chromosome protein HMG-I (Y) (25). This motif is typically
a short repeat of glycine and arginine flanked by a proline at one or both ends. The
central Arg-Gly-Arg of the AT-hook inserts into the minor groove of AT-rich DNA,
where there are interactions between arginine and thymidine (26). Many of the proteins
with AT-hook have been shown to have an effect on the architecture of chromatin at
levels beyond the action of the basic histones and also play a role in transcription
regulation (25).
Transmembrane domains are regions of a protein that are generally hydrophobic,
so they prefer to be inserted into cell membranes such that parts of the protein on either
side of the domain are on opposite sides of the membrane (27). Integral membrane
proteins have transmembrane domains that insert directly into lipid bilayers such as the
plasma membrane (28).
Glycosylation is one of the most common posttranslational modifications of
proteins and it plays a variety of important roles in many cellular events ranging from
structural to signaling and recognition (29). Glycosylation types are classified according
to the identity of the atom of the amino acid, which binds the carbohydrate chain, that is
N-linked, C-linked, O-linked or S-linked (30). FAM171B has four N-linked
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glycosylation sites according to bioinformatics analysis and this refers to the attachment
of oligosaccharides to a nitrogen atom, usually the N4 of asparagine residues. Nglycosylation often occurs on secreted or membrane bound proteins, mainly in eukaryotes
and archaea (30).
Based on the fact that FAM171B has a putative AT-Hook DNA binding domain,
one may hypothesize that FAM171B may function in the nucleus and perhaps bind DNA.
Alternatively, transmembrane domains suggest that FAM171B may instead localize to
cellular membranes such as ER, golgi or the plasma membrane. However, whether any of
these domains found in FAM171B actually function as predicted remains to be
empirically determined. Indeed, this study’s primary aim is to determine FAM171B’s
intracellular localization and shed light on whether any of these domains are in fact
biologically active.
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Objective
The overall objective of this project is to identify the intracellular localization of
FAM171B in several different nervous system cell types- a human glioblastoma cell line
(U138), a human neuroblastoma cell line (SH-SY5Y) and primary neurons harvested
from mouse brain.

Prediction
Based on the aforementioned bioinformatics data, FAM171B may function either
in the nucleus or as a membrane bound protein. Thus, we predicted that FAM171B would
localize to the nucleus or the plasma membrane (or both) of the cell.

To test this, we utilized both FAM171B-FLAG and FAM171B-GFP expression
vectors (previously constructed in the lab) to express FAM171B fusion protein in several
neuronal cell types. Transfected cells were fixed and analyzed using fluorescent confocal
microscopy to determine the subcellular location of FAM171B fusion proteins. We also
performed immunofluorescence on fixed U138 cells, SH-SY5Y cells and primary
neurons to examine endogenously expressed FAM171B using commercially available
antibodies. In addition, we performed co- immunofluorescence studies using an antibody
against Neu N (a marker for neurons) to ensure that at least some of the cells harvested
from mouse brains were indeed primary neurons. We also used organelle specific
markers to the nucleus, mitochondria, and endosomes to further establish subcellular
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localization. Finally, we conducted live-cell imaging on SH-SY5Y cells transfected with
FAM171B-GFP to help definitively determine its intracellular localization.
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Chapter 2
Materials and Methods

2.1 Culturing U138 cells

U138 cells were grown in Eagle’s Minimum Essential Medium (EMEM)
(supplemented with 10% fetal bovine serum). When cells were confluent (after 6-7 days)
the cells were split into a new 25 ml flask. First old media was removed from the cell
plate and 2 ml of phosphate buffered saline (1x PBS) was added to rinse and remove
residual media. Next, 2 ml of PBS+EDTA was added and incubated for 2 minutes to
detach cells from the plate. After 2-5 minutes in the incubator the cells detach from the
surface and then 2-3 drops of cells were added to a new 25 ml flask containing 6 ml of
EMEM media. This process was done weekly.

2.2 Culturing primary neurons

Mouse brains were purchased from Brain Bits LLC, and cultured according to
their protocol as follows.

Preparing cell dissociation solution
3 mL of hibernate solution (HE-Ca) was directly added into the 6 mg vial of
papain (2 mg/mL). The vial was recapped, gently mixed and then placed in a 30 °C water
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bath for 10 min to dissolve. After 10 min, the vial was removed from the water bath and
placed on ice to cool for 10 min.

Cell Dispersal
Using the Pasteur pipette the brain tissue was removed with minimal hibernate
(HEB) media and placed in the cell dissociation solution. The cell dissociation solution
was sealed and then incubated in the 30 °C water bath for 10 minutes, gently swirling for
every 5 minutes. Using the Pasteur pipet the tissue was removed with minimal cell
dissociation solution and placed the tissue back into the vial containing HEB media. With
the Pasteur pipette the tissue was drawn with the HEB media into the pipette and was
dispensed the content into the vial immediately. This was repeated for ~1 min for 90%
tissue dispersal. After this, the vial was not disturbed until undispersed pieces settle for 1
min. Next the supernatant containing dispersed cells was transferred to a sterile 15 mL
tube. This was spin at 1100 rpm (200xG) for 1 min. The supernatant was discarded
leaving ~ 50 µl of HEB media containing the pellet. The pellet of cells was dispersed by
flicking the bottom of the tube with a finger and re-suspended in 1 ml of NbActiv1
culture medium. After re-suspending, 32 µl of the cell dispersed solution was added on to
each well containing Poly-D-Lysine coated coverslips. Coverslips for primary neurons
were coated with Poly-D-Lysine solution to enhance the cell attachment. The amount cell
dispersed solution was increased based on the need of the cell density reducing the
number of cover slips used in successive experiments.
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2.3 Culturing SH-SY5Y cells

SH-SY5Y cells were growing in a media that was prepared using EMEM and F12 (1X) nutrient mixture (50:50). When the cells are confluent, cells were split into a new
T-25 Flask. First, culture media was transferred to a centrifuge tube. The flask was then
rinsed with 2 ml of PBS. Next, 2 ml PBS+EDTA was added and flask was incubated at
37 °C for 3 minutes. Contents of the flask were then transferred to the respective
centrifuge tube. The tube was then centrifuged for 3 minutes at 1000xg. Next the
supernatant was discarded and the cell pellet was resuspended in 4 ml of fresh media.
Then 1 ml of resuspended cells was added to a new flask containing 5 ml of fresh media.

2.4 Coverslip Preparation for Primary Neurons

Preparing coverslips with Poly-D-Lysine solution
Coverslips were added to each well in 6 well plates (10 plates) and sterilized
overnight under the UV light. The following day 150 µL of Poly-D-Lysine solution
(Brain Bits) was added onto the middle of each coverslip and incubated for 2-3 hours.
After incubation, excess Poly-D-Lysine was removed and the coverslips were rinsed with
tissue culture grade water (~1 ml per well). Next, the water was removed and coverslips
were allowed to air-dry. Prepared coverslips were stored at 4° C.
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2.5 Transfection with FAM171B-GFP

U138 cells were growing on coverslips in a 6 well plate (~5-6 drops of cells were
added to each well). The following day, 5 µg of plasmid FAM171B-GFP (678 ng/µl) was
added into 250 µL of opti-MEM media (for 6 wells = 30 µg /1500µL). Next, 10 µL of
Lipofecatamine 2000, a transfection reagent that is used to increase the transfection
efficiency of plasmid DNA, was diluted in 250 µL of opti-MEM (for 6 wells = 60
µL/1500µL). The two dilutions were let to sit for 5 minutes and then combined and
incubated for another 20 minutes. After 20 minutes 500 µL of the transfection material
was dripped down gently into each well containing U138 cells. This was incubated for 45 hours at 37 °C and media was changed into fresh EMEM. Next the transfected cells
were fixed in either Methanol or Paraformaldehyde (4%).

2.6 Transfection with FLAG-FAM171B

U138 cells were growing on coverslips in a 6 well plate (~5-6 drops of cells were
added to each well). The following day, 5 µg of plasmid FLAG-FAM171B (341 µg/ml)
was added into 250 µL of opti-MEM media (for 6 wells = 30 µg /1500µL). Next, 10 µL
of Lipofecatamine 2000, a transfection reagent that is used to increase the transfection
efficiency of plasmid DNA, was diluted in 250 µL of opti-MEM (for 6 wells = 60
µL/1500µL). The two dilutions were let to sit for 5 minutes and then combined and
incubated for another 20 minutes. After 20 minutes 500 µL of the transfection material

15
was dripped down gently into each well containing U138 cells. This was incubated for 45 hours and media was changed into fresh EMEM. Next, cells were fixed in methanol
and immunofluorescence protocol was followed as mentioned below with primary
antibody: Mouse anti FLAG (1:100) and secondary antibody Goat anti Mouse- Alexa:
568 (Novus) (1:600).

2.7 Cell Fixation

Methanol Fixation
First the media was removed and coverslips were rinsed in 1x PBS (2 ml per
well). Next, 2 ml of ice-cold methanol was added onto coverslips. Coverslips were fixed
for 3 min. After fixing, the coverslips were removed from methanol and allowed to airdry. If the fixation was performed after transfection procedure, coverslips were mounted
as described below. For immunofluorescence studies, below protocol was followed after
air-drying.

Paraformaldehyde Fixation
Similar to above, old media was first removed and coverslips were washed gently
with 1x PBS (2 ml per well) to remove old media and floating dead cells. Cells were then
be fixed with 1 ml of 4% paraformaldehyde solution for 15 min. at room temperature.
After fixing transfected coverslips, cells were washed 3 times with 1x PBS (2 ml per
well) and mounted onto slides as described below.
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When paraformaldehyde was used to fix the cells, additional steps were
performed as follows to increase the cell permeability before performing the
immunofluorescence procedure. After fixing coverslips with 4% paraformaldehyde for 15
min. cells were rinsed with 1x PBS 3 times (2 minutes wait time at each wash). Next,
cells were permeabilized with 0.2%- Triton –x100 in PBS for 3 minutes. In this step
coverslips were treated with 50 µl of this solution. Then coverslips were rinsed with 1x
PBS 3 times (2 minutes wait time at each wash) and once with 1x TBS. After these steps
were done, coverslips were subjected to blocking with TBS/10% milk and other steps
were followed as mentioned below for immunofluorescence procedure.

Mounting coverslips onto slides after the fixation
After fixing, coverslips were rehydrated by rinsing with 1x PBS twice (2ml per
well). After this, coverslips were rinsed with water. One drop of Vectashield mounting
medium (Vector laboratories) was added onto a microscope slide. Excess water was
removed from the coverslips by wicking, and then coverslips were slowly dropped onto
the drop of vectashield on the slide (cell side down). The four sides of the coverslip were
sealed using clear nail polish, and the prepared slides were analyzed using the confocal
microscope.
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2.8 Immunofluorescence

To perform IF experiments, fixed cells were rinsed with 2 ml of PBS (1x) three
times for 2 minutes. Then the coverslips were rinsed with 2 ml of TBS (1x) once for 2
minutes. After the rinsing steps, the coverslips were blocked in TBS/10% milk (50µl) for
2 hours at the room temperature in a humidified chamber. Next, the cells were incubated
with primary antibody Rabbit-FAM171B (Novus) (1:100) overnight at 4°C. Afterward
the cells were washed with 2ml of TBS/Tween 6 times for 5 minutes. After the washing
step, the cells were incubated with secondary antibody, Goat anti Rabbit – Alexa 488
(1:500) at the room temperature for 2 hours. Then the cells were rinsed with 2 ml of
TBS/T, 6 times for 5 minutes. The last step was to rinse the cells with deionized water
and then coverslips were mounted with 5 µl of Vectashield Antifade with DAPI. The
coverslips were then sealed using clear nail polish and the cells were observed using
confocal microscopy.

2.9 Confocal microscopy

Images were taken using the Zeiss LSM 880 confocal microscope. Per
experimental coverslip, minimum of 10 cells were analyzed. For every image taken in
this study, Plan-Apochromat 63x/1.4 NA oil objective lens was utilized. In Zen Blue 2.3
software, “locate” option was selected to enable the specimen to be viewed through the
ocular lenses and to find the region of interest in the specimen. All cells were grown on
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1.5 mm thickness coverslips specialized for this microscope and for live cell imaging a 4well chambered coverglass was used. To set the microscope for fluorescence observation,
blue/red/green emission channels were selected based on the staining we had on our cells.
Once the region of interest was found and focused, “acquisition” option was selected to
analyze the specimen in the computer using Zen blue 2.3 software. Confocal-4 color
parameter was selected each time for image acquisition. After scanning the image, “range
indicator” was activated, in which the scanned image appears in false-color
representation. Red pixel indicates the saturation (maximum intensity) and blue pixels
indicates zero or minimum intensity. To achieve the optimal intensity, with minimal
background signal, digital gain, digital offset and laser power parameters were adjusted.
The “snap” tool was used to acquire single frame (multi-channel) images. To better
evaluate the images, Z –stacking strategy was utilized. It is a digital image processing
method, which combines several images captured at several focal distances. This process
gives rise to composite image with a bigger depth of field than any of the individual
images from which the composite image is created. In acquiring Z-stack images, two
ends of the specimen were set using the focus knob and the interval between each stack
was set to optimal setting. Orthogonal views of the images in x, y and z planes were
studied to identify FAM171B localization inside the cell. To obtain the live cell imaging,
time-series option was utilized. The number of cycles and the interval between each
frame were selected based on the need of the duration of the video.
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2.10 Co-localization with a Mitochondrial marker

Immunofluorescence protocol was followed as mentioned above. Primary
antibody: Mouse anti Mitochondria (1:50) and secondary antibody: Goat anti Mouse:
Alexa 568 (1:500) were used with the primary and secondary antibodies of FAM171B.

2.11 Live cell

Live cell imaging was performed using confocal microscope on SH-SY5Y cells
after transfecting with FAM171B-GFP. First the cells were split in to a chambered
coverglass, specifically designed for live cell imaging (4 wells). The SH-SY5Y cell
pellet after centrifuging was resuspended in 2 ml of the media (refer to the SH-SY5Y
culture protocol above). Next 0.5 ml of resuspended pellet was added to each well in the
chambered coverglass. The following day, 1.25 µg of plasmid pEGFP-FAM171B (0.928
µg/ml) + 2.5 µL of P3000 reagent were added into 62.5 µL of opti-MEM media (for 4
wells = 5 µg+10 µL /250µL). Next, 2.5 µL of Lipofecatamine 3000, a transfection
reagent that is used to increase the transfection efficiency of plasmid DNA, was diluted in
62.5 µL of opti-MEM (for 4 wells = 10 µL/250µL). The two dilutions were then
combined and incubated for another 15 minutes at room temperature. After 15 minutes
125 µL of the transfection material was dripped down gently into each well containing
SH-SY5Y cells. Finally 1 µL of Hoechst nuclear stain was added to each well prior to the
imaging.
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2.12 Co-localization with early endosome marker in live cells

When performing live cell imaging with early endosome marker and FAM171BGFP, 2 µl of CellLight Early Endosome- RFP marker was dripped down to cell wells 30
seconds prior to adding the transfection reagents. Images were taken in between cycles of
20-300 with intervals ranging from 1.5 seconds to 2 seconds. Cells were maintained at
5% CO2, 37°C conditions. For each well 5-8 respective images were obtained using the
confocal microscope.
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Chapter 3
Results

3.1 Immunofluorescence using two different antibodies suggests that FAM171B
localizes to punctate vesicles in the cytoplasm of Primary neurons, SH-SY5Y
Neuroblastoma cells and U138 Glioblastoma cells.

We performed immunofluorescent experiments using two commercially available
primary polyclonal antibodies (Novus 93847) and (Novus 93846) to assay FAM171B’s
intracellular localization in several different neuronal cell lines (Figures 1 and 2). The
Novus 93847 Ab showed that FAM171B localizes predominantly to the cytoplasm of
cells in discrete punctate dots reminiscent of small endomembrane system vesicles
(Figure 1). Occasionally it appeared that FAM171B may be in/near the nucleus of certain
cells (co-stained with DAPI); however, Z-stack images taken using the confocal
microscope suggested that FAM171B predominantly localized to the cytoplasm (Figures
3-5). Interestingly, all three cell lines (glioblastoma, neuroblastoma and primary
neurons) showed very similar staining patterns (Figure 1) suggesting that this is likely
FAM171B’s intracellular distribution in many/most nervous system cell types.
Importantly, we confirmed these results using a second primary antibody raised against a
different epitope of FAM171B (Figure 2). Indeed, Novus 93846 primary Ab showed very
similar staining patterns with punctate/vesicular type staining of FAM171B throughout
the cytoplasm of all three cell lines (Figure 2).
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Merged

A)

U 138
B)

SH-SY5Y
C)
P. Neuron
Figure 1: FAM171B displays a punctate cytoplasmic staining in primary neurons,
SH-SY5Y cells and U138 cells (Immunofluorescence, Novus 93847 rabbit polyclonal
Ab). Blue indicates DAPI nuclear stain and green indicates the expression of FAM171B.
Methanol was used for fixation in each cell line.
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A)

U 138
B)

SH-SY5Y
C)
P. Neuron
Figure 2: FAM171B displays punctate cytoplasmic staining in primary neurons, SHSY5Y cells and U138 cells. (Immunofluorescence, Novus 93846 rabbit polyclonal
Ab). Blue indicates DAPI nuclear stain and green indicates the expression of FAM171B.
Methanol was used for fixation in each cell line.
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Figure 3: Orthogonal view of the merged image of U138 (Immunofluorescence,
Novus 93846 rabbit polyclonal Ab) indicates FAM171B predominantly localizes to
the cytoplasm of the cell. Blue indicates DAPI nuclear stain and green indicates the
expression of FAM171B.
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Figure 4: Orthogonal view of the merged image of SH-SH5Y (Immunofluorescence,
Novus 93846 rabbit polyclonal Ab) indicates FAM171B predominantly localizes to
the cytoplasm of the cell. Blue indicates DAPI nuclear stain and green indicates the
expression of FAM171B.
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Figure 5: Orthogonal view of the merged image of primary neuron
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab) indicates FAM171B
predominantly localizes to the cytoplasm of the cell. Blue indicates DAPI nuclear stain
and green indicates the expression of FAM171B.
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3.2 FAM171B-GFP expression in fixed U138 cells

Exogenous expression of FAM171B was then studied by transfecting U138 cells
with a FAM171B-GFP fusion protein plasmid (previously constructed in the lab). Similar
to what we observed with immunofluorescence, FAM171B-GFP expression was
predominantly localized to the cytoplasm of transfected cells (Figure 6). Also,
FAM171B-GFP had a similar cytoplasmic vesicular staining pattern and intriguingly it
could be seen more concentrated closer to the plasma membrane. These data suggest that
endogenous and exogenous expression of FAM171B is very similar.
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DAPI

FAM171B

Merged

Figure 6. FAM171B-GFP displays a punctate signaling pattern in U138 cells (fixed).
Blue indicates DAPI nuclear stain and green indicates FAM171B (Methanol was used for
fixation and 5 µg of plasmid was used in this experiment).
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Figure 7: Orthogonal view of transfected U138 cell with FAM171B-GFP (merged
image) indicates FAM171B localizes predominantly to the cytoplasm of the cell.
Blue indicates DAPI nuclear stain and green indicates FAM171B.
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3.3 FAM171B-FLAG expression in fixed U138 cells

DAPI

FLAG

Merged

Figure 8: FAM171B-FLAG localizes to the cytoplasm of U138 cells. Red signaling
indicates the expression of FAM171B and DAPI in blue indicates the nucleus. Methanol
was used for fixation.

To further examine the exogenous expression of FAM171B and its intracellular
localization, we utilized a second fusion protein, FAM171B-FLAG (previously
constructed in our lab) to transfect U138 cells. FAM171B-FLAG also localizes to the
cytoplasm of the cell and displays a vesicular/punctate-staining pattern (Figure 8), similar
to what we witnessed in transfection studies with GFP fusion protein and
immunofluorescence data. This further validates the similarity between the endogenous
and exogenous expression of FAM171B.
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Figure 9: Orthogonal view of the merged image of U138 cell transfected with
FAM171B-FLAG shows FAM171B predominantly localizes to the cytoplasm of the
cell. Red signaling indicates the expression of FAM171B and DAPI in blue indicates the
nucleus.
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In order to analyze whether this punctate signaling pattern changes with different
amounts of plasmid, U138 cells were subjected to transfection with varying amounts of
FAM171B-GFP plasmid, ranging from 10 ng to 10 µg. It was observed that at each
plasmid concentration, FAM171B’s punctate/ vesicular signaling pattern continued to be
consistent, confirming that plasmid concentration does not affect the signaling pattern of
the protein (Figure 10). At lower concentrations of the plasmid, the number of transfected
cells was reduced and 5 µg of plasmid was used in our successive experiments. Moreover
two fixing methods were tested: paraformaldehyde and methanol. We found no
differences in expression pattern between the two fixing methods and methanol was used
in most experiments (data not shown). Figure 10 shows transfections with three lower
concentrations of FAM171B-GFP plasmid: 10ng, 100ng, 500ng, and at each
concentration, FAM171B shows the same signaling pattern.
A)

B)

C)

Figure 10: FAM171B-GFP exhibits similar expression pattern at different plasmid
concentrations. Image A) indicates transfection with 10ng, B) with 100ng and C) with
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500ng. Green signaling depicts FAM171B signaling and blue signaling depicts where the
nucleus is. Methanol was used for fixation.

3.4 Co-immunofluorescence of FAM171B and NeuN in primary neurons

DAPI

NeuN

FAM171B

Merged

Figure 11: FAM171B is expressed in the cytoplasm of neurons. Red indicates the
NeuN signaling, green indicates the FAM171B expression (Novus 93846 polyclonal
antibody) and nucleus is stained in blue with DAPI. Methanol was used for fixation.
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Primary neurons in our study were harvested from mouse brain cerebellum
purchased from Brain Bits LLC. To confirm the cells we study are indeed neurons,
NeuN, a neuronal biomarker that is used to identify neurons was utilized. Harvested
primary neurons were subjected to co-immunofluorescence using antibodies against
FAM171B (Novus 93846) and against NeuN (Figure 11). Red signaling indicates the
staining of NeuN, which signifies the presence of primary neurons. This confirmed that
the cells we were analyzing were indeed neuronal cells.

3.5 Co-immunofluorescence of FAM171B and mitochondria in primary neurons

In attempt to identify the subcellular localization of the FAM171B in the cell,
different organelle markers were utilized to analyze possible co-localization. Primary
neurons were subjected to co- immunofluorescence with antibodies against mitochondria
in the neurons and with antibodies against FAM171B (Figure 12). Based on the acquired
data it was noticed that FAM171B does not co-localize with mitochondrial organelles, as
little signal overlap was detected (Figure 13). This indicated that FAM171B protein
might not function in mitochondrial activity in the cell.
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Figure 12: FAM171B does not co-localize to mitochondria in primary neurons. Red
signaling indicates the mitochondria and green signaling indicates the FAM171B
expression (Novus 93846 polyclonal antibody). Methanol was used for fixation.
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Figure 13: Orthogonal view of the merged image of primary neuron, subjected to
co-immunofluorescence with antibody against FAM171B (Novus 93846) and
mitochondria. FAM171B does not co-localize well with mitochondria.
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3.6 Pseudopod-like protrusions.

Figure 14: FAM171B localizes to pseudopod protrusions near the plasma
membrane in cells. U138 cell was subjected to IF and green signaling indicates the
expression of FAM171B (Novus 93847 polyclonal antibody).

We observed that FAM171B signals localizes to cellular regions near plasma
membrane that resembles pseudopod-like cellular structures. Interestingly, this cellular
characteristic was observed in both fixed and live cell imaging (SH-SY5Y cells).
Enlarged cross sections of U138 cells depicted above (Figure 14) show pseudopod like
plasma membrane protrusions and vesicular FAM171B signaling could be seen alongside
the edges of these membrane protrusions. When analyzing static images, Z-stack images
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were obtained (taking multiple images at different focal distances) and these membrane
protrusions were noticed at certain stacks.

3.7 Live- cell imaging

To gain more insight on FAM171B’s expression in real time in its cellular
environment, we performed live cell imaging on SH-SY5Y cells. We first transfected the
cells with FAM171B-GFP and live cell imaging showed vesicular green particles moving
in the cytoplasm of the cell resembling the process of vesicular trafficking (Link 1). Also
there were pseudopod like protrusions emanating from the edges of the plasma membrane
of these live cells (Link 2) which was also observed in Z-stack images of the fixed
transfected U138 cells and cells that were subjected to immunofluorescence. Interestingly
it could be seen that these dynamic cellular structures in live cells were constantly
extending and retracting from the cell membrane.
Next the live cells were co-stained with early endosome marker after transfecting
the cells with FAM171B-GFP. It was observed that approximately one-half of the
FAM171B-GFP signaling localizes to early endosome in live SH-SY5Y cells suggesting
FAM171’s possible function in endocytic processes (Link 3). Cell nuclei were stained in
blue using the Hoechst DNA stain, and again FAM171B expression was typically not
found in the nucleus. Figure 15 below shows a screen capture of live-cells after costaining with early endosome.
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Figure 15: FAM171B co-localizes with early endosomes in live SH-SY5Y cells. Green
signaling: expression of FAM171B and red: expression of early endosome in the cell.
Blue signaling indicates the nucleus of the cell and yellow signaling indicates the colocalization of FAM171B and early endosomes (red arrows).

Link 1:
SH-SY5Y Neuroblastoma cells : 33 hours post-transfection: This live-cell video shows
the punctate vesicular signaling of FAM171B in SH-SY5Y cells, moving in the
cytoplasm (60 seconds).
Link 2:
SH-SY5Y Neuroblastoma cells: 31 hours post-transfection: This video shows an enriched
staining of FAM171B near the plasma membrane and highlights the dynamic cellular
protrusions of the live cells similar to what was observed in fixed cells (6 seconds).
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Link 3:
SH-SY5Y Neuroblastoma cells: Co-localization with early endosomes: 72 hours posttransfection: This video shows co-localization of FAM171B with early endosomes.
Yellow signaling specifies the overlap of FAM171B with early endosomes (4 seconds).
Static images of this video are illustrated above.
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Chapter 4
Discussion

FAM171B is a novel polyQ protein with 14 glutamine repeats in its amino acid
sequence. There is minimal published data regarding this protein and its location and the
function are yet to be determined. Based on characteristics it shares with other
neurodegenerative diseases caused by abnormal expansions in the polyQ regions,
FAM171B could also be linked to another molecularly uncharacterized
neurodegenerative disease. Previous research conducted in our lab found that this novel
protein is expressed widely throughout the developing and adult mouse brain through two
different approaches, in situ hybridization and immunohistochemistry analysis. Moreover
it was found that expression levels are more prominent in some brain regions compared
to others.
The purpose of the current research was to further expand the knowledge of this
protein by looking into the intracellular localization. Proteins are responsible for a
multitude of diverse vital tasks in all living organisms. Given that a protein’s function
and role are strongly related to its subcellular location, protein location prediction is an
important research area (31). It can provide useful insights about their functions,
particularly, one of the fundamental goals in cell biology and proteomics is to identify the
functions of proteins in the context of compartments that organize them in the cellular
environment (32). It can indicate how and in what kind of cellular environments the
proteins interact with each other and with other molecules, this is especially important for
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the in-depth study of protein-protein interaction (PPI). Also it can help our understanding
of the intricate pathways that regulate biological processes at the cellular level and hence
it is crucial for many studies in system biology (33). Furthermore it is very useful for
identifying and prioritizing drug targets during the process of drug development (32).
To obtain intracellular localization data of FAM171B, three different cell lines
were used in this study: human glioblastoma cells (U138), human neuroblastoma cells
(SH-SY5Y) and mouse primary neurons. Furthermore, two distinct approaches were
utilized- immunofluorescence (with two separate antibodies) and fusion protein
expression using both FLAG and green fluorescent protein (GFP) tags. Cells were also
fixed using two different approaches (methanol and paraformaldehyde). In addition,
colocalization with subcellular markers (nucleus, mitochondria, and endosomes) was
performed. Finally, time-lapse imaging of SH-SY5Y live cells expressing FAM171BGFP was performed to further understand the dynamic nature of FAM171B movement
within cells.
Immunofluorescence (IF) was studied in all three cell lines and our data showed
that FAM171B displayed a consistent punctate/vesicular type expression pattern (Figures
1,2). This signaling predominantly localized to the cytoplasm of the cell and this
characteristic was observed in every cell line and fixation method used. Z-stack images of
the cells were taken to create 3D images and those images were used to confirm that
FAM171B is expressed in the cytoplasm (Figures 3-5).
Next, cells were transfected with plasmids created in our lab to confirm whether
the endogenous and exogenous expression of the FAM171B is similar (Figures 6,8).
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Cells were first transfected with FAM171B-GFP, and we found that FAM171B-GFP
signaling localizes to the cytoplasm of the cell, and displayed a punctate/vesicular type
signaling in the cytoplasm similar to IF data for FAM171B (Figure 6). Different
quantities of plasmid were used with varying amounts of Lipofectamine 2000
(transfection reagent) to transfect the cells to analyze if the signaling pattern changes
based on the plasmid/transfection reagent concentration (Figure 10). The signaling
pattern continued to display the same cytoplasmic punctate/vesicular stain, although we
observed that at lower plasmid concentrations only few cells were transfected and at high
concentration more cells were transfected (Figure 10).
Next, cells were transfected with a different FAM171B fusion protein constructed
in our lab. This fusion protein has a tag called FLAG, consisting of eight amino acids
(AspTyrLysAspAspAspAspLys) (34) and immunofluorescence was performed with
antibodies against FLAG peptide sequence. FLAG-FAM171B signaling, similar to the
GFP transfection and IF data, was localized to the cytoplasm of cells further validating
our data (Figure 8).
After analyzing the IF and transfection data it was noted that FAM171B is a
cytoplasmic protein and next we tried to utilize organelle specific markers to find the
subcellular location of the protein. First, primary neurons were stained with a
mitochondrial marker and our data indicated that FAM171B and mitochondria do not colocalize well as little signal overlap was observed (Figures 12,13). We are confident that
FAM171B is present in the cytoplasm of neurons as a number of the primary cultured
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cells derived from the mouse brain also stained for the neuronal marker NeuN (Figure
11).
The punctate/vesicular expression suggests that FAM171B could be a protein
associated with vesicular transport. To further explore this possibility, we utilized an
early endosomal marker in conjunction with FAM171B-GFP and found a strong
colocalization between the two (Figure 15). Indeed, when subjected to live cell imaging
these two vesicle compartments moved in tandem in the same direction (Figure 15, Link
3). These results strongly suggest that FAM171B is at least occasionally present in
endosomes. Thus, FAM171B may play a role within vesicular trafficking system
(specifically endosomes) or it may itself be trafficked as cargo either in or out of the cell.
Transport vesicles play a central role in the traffic of molecules between different
membrane-enclosed compartments of the secretory pathway and endocytic pathway
which is important for organelle biogenesis, constitutive and regulated secretion and
endocytosis (35,36).
Efficient sorting of the material internalized by endocytosis is essential for key
cellular functions and represents a major trafficking pathway in mammalian cells (37).
Incoming material such as solutes, receptors and cargos, lipids and even pathogenic
agents are routed to various destinations within mammalian cells at two major sorting
stations: the early and late endosome (37). Sorting events initiated at early endosomes
determine the subsequent fate of internalized proteins and lipids, destining them either for
recycling to the plasma membrane, degradation in lysosomes or delivery to the transgolgi network (38). The late endosome provides a central hub for incoming traffic from
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the endocytic, biosynthetic and autophagic pathways and outgoing traffic to the
lysosomes, the golgi complex or the plasma membrane (37). Our data suggest that
FAM171B could be a protein functioning in cellular endocytosis since approximately
half of our GFP-FAM171B signaling was co-localizing with early endosome markers in
live-cell imaging and due to the punctate/ vesicular type expression in live and fixed
cells. Moreover these vesicular structures were denser in the peripheral area of the cell
where early endosomes usually reside in the cell.
Furthermore it was observed that these cells (fixed and live) show pseudopod-like
protrusions around the edges of the cell membrane (Figure 14, Link 2). In fixed cells it
was detected at different Z-stacks. In these protrusions FAM171B vesicles could be
detected. These protrusions were prominent in live-cell imaging, and could be seen
growing and retracting over the course of minutes (Link 2). The ability of cells to extend
cell membranes is central to numerous biological processes, including cell migration,
axon pathfinding, cadherin-mediated junction formation and phagocytosis (39). Moreover
plasma membrane regions that form new protrusions could arise from the flow of
membrane components from other regions of the cell, including vesicles such as
endosomes (40).
Basquin et al (41), revealed a new mechanism that they call protrusion-based
endocytosis, which is used to internalize receptors into small vesicles. In their work, they
showed that interleukin-2 receptor (IL-2R) endocytosis requires its recruitment at the
base of protrusions via its association with the WAVE complex (41). The WAVE
complex is a nucleation-promoting factor activating the actin-related proteins 2 and 3
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complex, inducing actin polymerization and membrane protrusion (41). These findings
suggest that the cellular protrusion we observed in our cells could be playing a role in
endocytosis further supporting FAM171B’s possible function in the process.
One more possibility of these cellular protrusions observed in static and live cells
is that this could be functioning in axon path finding or synapse formation
(synaptogenesis). A common theme regarding the synaptogenesis is that growing axons
explore their pathways and target regions by elaborating many dynamic, often transient
protrusive filopodia and branchlets (42). Filopodia are long and slender cellular
protrusions, which are one of the types of pseudopoda, have roles spanning the initiation
and guidance of neuronal processes, axons and dendrites (43). This highly protrusive
behavior of filopoda appears to be essential to the axon’s ability to pathfind and locate
appropriate target cells (42). Extensions and retractions of cellular protrusions was a
prominent feature in our live cell imaging of SH-SY5Y cells.
In order to further evaluate this position, future studies could include studying colocalization of FAM171B with other organelle markers such as late endosomes. Also if
this protein is functioning in endosome activity and if the expression of this protein is
inhibited by gene knock out, complications in endocytosis process would be expected to
be seen. Moreover pseudopod like protrusions might also be inhibited if the gene for
FAM171B is deleted.
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Conclusion

FAM171B is a novel polyglutamine protein with 14 glutamine repeats in its
amino acid sequence. There is minimal publish data regarding this protein such that its
function and its intracellular location have yet to be discovered. Based on the homology
this protein shares with other polyQ neurodegenerative diseases, this could also be linked
to another unknown polyQ disease. Previous research done in our lab found out that this
protein is widely expressed throughout the mice brain using two different approaches: insitu hybridization and immunohistochemical identification. This current research was
undertaken to figure out the intracellular location of this protein using
immunofluorescence and transfection studies. Our data indicate that FAM171B
predominantly localizes to the cytoplasm of the cell. This was consistent between every
cell line we analyzed. Expression pattern displayed a punctate/vesicular signaling and
these signaling was more pronounced closer to the plasma membrane of the cell. Livecell imaging data revealed that FAM171B-GFP localized to early endosomes. Moreover
pseudopods like cellular cell membrane protrusions were observed in static and live cells.
Taken together, these data suggest that FAM171B may play a role in cellular activities
near the plasma membrane such as endocytosis and/or axon pathfinding. If FAM171B is
linked to an unknown neurodegenerative disease, it could be contributing to the
pathogenesis by disrupting the endosome function or by inhibiting the formation of
neural circuits.
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